Inflammation and enhanced nociceptive responses to bladder distension produced by intravesical zymosan in the rat by Randich, Alan et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Urology
Open Access Research article
Inflammation and enhanced nociceptive responses to bladder 
distension produced by intravesical zymosan in the rat
Alan Randich1, Tyler Uzzell2, Ronda Cannon2 and Timothy J Ness*2
Address: 1Department of Psychology, University of Alabama at Birmingham, Birmingham, Al, 35294, USA and 2Department of Anesthesiology, 
University of Alabama at Birmingham, Birmingham, Al, 35294, USA
Email: Alan Randich - arandich@uab.edu; Tyler Uzzell - hess@uab.edu; Ronda Cannon - paintech@uab.edu; Timothy J Ness* - loch@uab.edu
* Corresponding author    
Abstract
Background: Mycotic infections of the bladder produce pain and inflammatory changes. The
present study examined the inflammatory and nociceptive effects of the yeast cell wall component,
zymosan, when admininstered into the urinary bladder in order to characterize this form of bladder
sensitization.
Methods: Parametric analyses of the time-course (0–48 hr) and concentration (0–2% solutions)
variables associated with intravesical zymosan-induced bladder inflammation were performed in
female rats. Plasma extravasation of Evan's Blue dye was used as a measure of tissue inflammation.
Cardiovascular and visceromotor responses to urinary bladder distension were used as measures
of nociception.
Results: Zymosan-induced bladder inflammation, as indexed by plasma extravasation of Evan's
Blue, was significantly greater in rats treated with either 1 or 2% solutions as compared to either
0.1 or 0.5% zymosan solutions. In time-course studies (1 – 48 hr post-treatment), 1% zymosan-
induced inflammation progressively increased with time following administration, was greatest at
24 hr and began to normalize by 48 hr. In the studies of inflammation-induced changes in
nociception, arterial blood pressure (ABP) and visceromotor responses to graded distension of the
urinary bladder were significantly increased relative to controls 24 hr after zymosan administration.
Conclusion: These studies provide important time-course and solution concentration parameters
for studies of zymosan-induced inflammation of the bladder and suggest utility of this model for the
study of bladder-related pain.
Background
Our knowledge of inflammation-induced changes in
bladder tissue that result in bladder-related pain is lim-
ited. Bacterial, mycotic and viral infections of the urinary
tract are all potential etiologies of bladder inflammation
[1]. Our understanding of the neural substrates that are
altered by infectious processes is virtually nonexistent.
Recent studies have demonstrated that the injection of the
substance lipopolysaccharide (LPS), derived from the cell
wall of E. Coli bacteria, activates the innate immune
mechanisms (Toll-like receptor 4-related) that are nor-
mally activated by infection [2]. Mycotic infections, such
as those produced by Candida Albicans, activate similar,
but distinctly different innate immune mechanisms [3,4].
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Zymosan is a mycotic equivalent to bacterial LPS in that it
is yeast cell wall derivative which activates the Toll-like
receptor 2 (TLR2) and the alternate complement pathway
[4]. Zymosan can be viewed as a "natural" inflammogen
which produces a receptor-mediated reactive cellular
process as opposed to chemical irritants which result in
frank, extensive tissue damage that leads to inflammation.
Zymosan has been extensively characterized in behavio-
ral, primary afferent, and dorsal horn neuron studies of
cutaneous inflammation [e.g., [5,6]]. A robust colitis also
is produced by intracolonic administration of zymosan
[7], but no one has reported on the use of zymosan in
other visceral structures.
Only a few validated animal models of visceral nocicep-
tion exist (for review, see [8]). Those that have been vali-
dated typically have used observations of animal
posturing as well as reflex increases in arterial blood pres-
sure (ABP) and electromyographic (EMG) activity of the
abdominal muscles (visceromotor reflex) as response
measures of visceral nociception. The presence of inflam-
mation has been demonstrated to be a potent enhancer of
responses to visceral stimuli. In particular, inflammation
of the colorectal mucosa by the intracolonic application
of turpentine [9,10], acetic acid [11,12], trinitrobenzene
sulfonic acid [13] as well as zymosan [7] has been demon-
strated to magnify reflex ABP and EMG responses to dis-
tension of the colon (CRD). In humans, inflammation
also frequently leads to an enhancement of visceral pain
sensations and so animal models demonstrating an
enhancement of responses to a visceral stimulus produced
by inflammation support the use of the models as behav-
ioral indices of nociception.
Recently, we [14,15] proposed using similar response
measures evoked by urinary bladder distension (UBD) as
an animal model of bladder pain. In our initial studies, we
found these measures to be reliable and valid indices of
bladder nociception in the rat with responses inhibited by
analgesic manipulations. In the present studies, we sought
to determine whether these response measures were
affected by inflammation of the urinary bladder using
zymosan as an inflammogen by determining the optimal
concentration and time-course parameters for producing
zymosan-related inflammation of the bladder as meas-
ured by Evan's Blue-related plasma extravasation and then
correlating these inflammatory changes with nociceptive
responses evoked by UBD of the inflamed bladder.
Plasma extravasation of Evan's Blue dye has been vali-
dated as a measure of local inflammation in numerous
previous studies [16-18].
Methods
General
Adult, female Sprague Dawley rats were obtained from
Harlan Laboratories (Prattville, AL) and housed in group
cages. Food and water were provided on an ad libitum
basis. These studies were approved by the University of
Alabama at Birmingham Institutional Animal Care and
Use Committee.
Experiment 1 – Time-course of inflammatory responses
This experiment determined the time-course of inflamma-
tion produced by the intravesical administration of
zymosan into the urinary bladder. Inflammation was
measured as a function of the amount of Evan's Blue
plasma extravasation into the bladder using a slight varia-
tion on previously published methodology [10,16-18].
Separate groups of rats (N = 5 for all groups) received
either no treatment (naive group), or received intravesical
administration of either saline (0.5 ml) or a 1% zymosan
solution (0.5 ml). Rats receiving treatments were anesthe-
tized with halothane (1–5%) by mask to provide immo-
bility for the placement of a 22-gauge angiocatheter into
the urinary bladder via the urethra without trauma. Solu-
tions were then administered and left in place for 30 min-
utes. Bladders were then drained and rats recovered from
anesthesia. To prevent the introduction of infection into
the bladders a povidone surface preparation was per-
formed prior to catheterization and each treated rat
received 50–100 mg/kg of ampicillin (s.c.). Groups of rats
receiving zymosan were tested 1, 4, 12, 24, or 48 hr after
their treatment. The saline control group rats were tested
24 hr after their treatment. Saline administration was used
to control for all aspects of the procedure excluding
inflammation, e.g., placement of the transurethral cathe-
ter and bladder distension. At the time of testing, all rats
were reanesthetized and administered Evan's Blue (50
mg/kg i.v. via external jugular) which was allowed to cir-
culate for 15 min. Animals were euthanized with pento-
barbital (100 mg/kg i.v.) and perfused intracardially with
500 ml of normal saline. Whole bladders were removed
and placed in 10 ml of dimethylsulfoxide for subsequent
analysis. The amount of Evan's Blue extracted from the
bladder tissue was determined spectrophotometrically
(620 nm) and data were expressed in µg/g of bladder
weight.
Experiment 2 – Effect of Zymosan concentration
This experiment determined the effect of zymosan con-
centration on the degree of plasma extravasation of Evan's
Blue in the bladder. The same general procedures were
used as described in Experiment 1 except that separate
groups of rats (N = 5 per group) received intravesical
administration of differing concentrations of zymosan
(0.1, 0.5, 1.0, and 2.0%) in normal saline and the Evan'sBMC Urology 2006, 6:2 http://www.biomedcentral.com/1471-2490/6/2
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Blue determination was performed 24 hr later. The 1%
zymosan data were those derived from Experiment 1.
Experiment 3 – Time-course of effects on nociceptive 
reflexes
This experiment determined the time-course of the effects
of intravesical administration of zymosan on abdominal
EMG and systemic ABP responses to UBD. Separate
groups of rats (N = 6–21/group) were treated similarly to
those described in Experiment 1: rats received either no
treatment (naive), or intravesical administration of either
saline (0.5 ml) or a 1% zymosan solution (0.5 ml).
Zymosan-treated rats were tested at 4, 12, 24, or 48 hr
after their treatment and the saline control group was
tested at 24 hr. Methodology is the same as that previously
published [15]. Briefly, at the time of testing, each rat was
re-anesthetized with halothane and instrumented for car-
diovascular and EMG measures. Carotid arterial and tra-
cheal cannulae were inserted for recording of ABP and
artificial respiration, respectively under deep halothane
anesthesia (2–5%). The right vagus nerve is sometimes
injured during carotid manipulation and so to provide
consistency between preparations was formally
transected. The left abdominal skin was incised and silver
wires were sutured to the external oblique abdominal
musculature allowing for differential amplification of
EMG activity. A 22-gauge angiocatheter was placed into
the urinary bladder via the urethra and held in place by a
tight ligature around the distal urethral orifice.
Following completion of the surgical preparation, the
halothane anesthesia was reduced until flexion reflex
responses could be evoked by pinch of the foot but with-
out spontaneous escape behaviors (typically 0.5–0.7%
halothane). The rats were artificially ventilated and not
restrained in any fashion. Body temperature was main-
tained using a heating pad and overhead radiant lights. All
data were saved on computer using MacIntosh-based
Spike-2 software and associated hardware (Micro 1401;
CED, Cambridge, UK) and a similar MacLab system
(Stoelting, Inc).
All rats received multiple distensions of the urinary blad-
der via the intravesical catheter. An in-line, pneumatically-
linked, low volume pressure transducer was used to mon-
itor intravesical pressure. Pressure within the bladder was
Indices of bladder inflammation using Evan's Blue extravasation as an experimental endpoint Figure 1
Indices of bladder inflammation using Evan's Blue extravasation as an experimental endpoint. Panel A presents group mean 
Evan's Blue concentration (µg/g) obtained 1, 4, 12, 24, or 48 hr after intravesical administration of 1% zymosan. Groups 4 hr 12 
hr, and 24 hr did not differ from each other but were significantly greater than either groups 1 hr, 48 hr, naive control (open 
circle), and saline control (open triangle) as denoted by *. Panel B presents group mean Evan's Blue concentration obtained 
from rats receiving 0.1, 0.5, 1.0, or 2.0% intravesical zymosan administration 24 h previously. * denote significantly different 
from 0.1 and 0.5% groups. For all groups in A&B, N = 5. Error bars indicate SEM.BMC Urology 2006, 6:2 http://www.biomedcentral.com/1471-2490/6/2
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Enhancement of nociceptive responses to urinary bladder distension (UBD) Figure 2
Enhancement of nociceptive responses to urinary bladder distension (UBD). Panel A presents group mean EMG as a function 
of UBD pressure – a typical EMG response to a 60 mm Hg UBD is given as an inset. The 24 hr zymosan-treated group differed 
significantly (p < 0.05) from the naive and saline control groups as denoted by *. Panel B presents group mean ABP as a func-
tion of UBD – a typical pressor response to a 60 mm Hg UBD is given as an inset. The 24 hr zymosan-treated group differed 
significantly from the naive and saline control groups as denoted by *. In A & B all other comparisons were not statistically sig-
nificant. Note: the number of subjects given in B is less than those in A due to occasional technical difficulty with ABP measure-
ments. Symbols are per inset legend (controls with open symbols; zymosan-treated with filled symbols). Error bars indicate 
SEM.BMC Urology 2006, 6:2 http://www.biomedcentral.com/1471-2490/6/2
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controlled using a pressure control device [19]. Three 60
mmHg, 20 second UBDs (4 min intertrial interval) were
administered followed by 20 second, constant-pressure
air distensions of the urinary bladder at pressures of 10,
20, 30, 40, 50, and 60 mmHg, respectively.
ABP was measured continuously via the pulse pressure
signal from the arterial cannula. In tests of UBD, an ABP
response was defined as the peak change in mean ABP
(?mmHg) during UBD as compared with the average
response during a baseline period immediately prior to
UBD. The EMG response was electronically rectified and
normalized to baseline electronic "noise" levels (the low-
est EMG activity level recorded from any particular rat.)
These signal-to-noise ratios were defined as the EMG
response to UBD and consisted of the following: (mean
rectified EMG activity during UBD – mean rectified base-
line EMG measured immediately prior to UBD) / (mean
rectified baseline EMG noise level).
Statistics
Data are presented as the mean ± S.E.M. unless otherwise
stated. ABP and EMG responses to UBD are presented as
change from baseline measures. One way ANOVAs were
used for Evan's Blue data and repeated measures ANOVAs
were used for ABP and EMG. Statistical significance was
defined as p values ≤ 0.05.
Results
Experiment 1 – Time course of inflammatory response
Panel A of Figure 1 shows that group mean plasma
extravasation of Evan's Blue systematically increased from
1 to 24 hr after intravesical administration of 1% zymosan
and then returned to low levels by 48 hr. A between-
groups ANOVA revealed a significant effect of time and
Fisher's post-hoc comparisons indicated that the 4, 12,
and 24 hr zymosan groups were significantly greater than
either the 1 hr or 48 hr zymosan groups (p < 0.05), but did
not differ from one another. In addition, the 4, 12, and 24
hr zymosan group means were significantly greater than
those of the non-pretreated (naive) and saline-treated
control groups (p < 0.05).
Experiment 2 – Effect of Zymosan concentration
Panel B of Figure 1 shows that the amount of plasma
extravasation of Evan's Blue systematically increased as a
function of the concentration of zymosan instilled into
the bladder 24 hr prior to testing. An ANOVA revealed sig-
nificant between-groups differences and Fisher post-hoc
comparisons indicated that the 0.1% and 0.5% group
means did not differ, but that they were significantly less
than either the 1.0% and 2.0% groups whereas the latter
two groups did not differ.
Experiment 3 – Time-course of effects on nociceptive 
reflexes
Panel A of Figure 2 presents the group mean EMG
responses evoked by UBD in groups tested at various
times after bladder instillation of a 1% zymosan solution.
Only the 24 hr post-zymosan condition showed
enhanced EMG responses compared to naive and saline
control groups. An ANOVA indicated a significant overall
group effect, F(5,59) = 3.16. The subsequent post-hoc
comparisons revealed that the group mean EMGs of the
naive and saline groups did not significantly differ, but
that the means of these groups combined were signifi-
cantly less than the group mean EMG of the 24 hr group.
Similar comparisons of the naive and saline control data
with all other zymosan time conditions failed to attain
statistical significance.
Panel B of Figure 2 shows the group mean ABP responses
to UBD in the same groups of rats described in Figure 2A.
As was true of the EMG measures, only the 24 hr post-
zymosan condition showed enhanced ABP responses to
UBD with all other groups showing responses of compa-
rable magnitude to both the naive and saline control
groups. An ANOVA indicated a significant overall group
effect, F(5,54) = 3.24. Subsequent post-hoc comparisons
revealed that the group mean ABP responses of the naive
and saline groups did not significantly differ, but these
groups combined were significantly less than the group
mean ABP obtained in the 24 hr group. Similar compari-
sons of the naive and saline control data with all other
zymosan time conditions failed to attain statistical signif-
icance.
Discussion
The most important finding of the present study was that
the yeast cell wall component, zymosan, which evokes
innate immune responses in a fashion similar to mycotic
infections, led to an inflamed bladder and magnified
reflex responses to bladder distension. Specifically, the
present studies parametrically characterized multiple var-
iables associated with the zymosan-induced model of
bladder inflammation including the effect of time and
solution concentration. Within the parameters tested, a
single 30 minute instillation of a 1% zymosan solution
resulted in a significant inflammatory response in the
bladder as early as 4 hr after administration. This response
peaked at 24 hr and by 48 hr was returning to control lev-
els. This study also showed that both 1 and 2% concentra-
tions produced significantly greater responses than the 0.1
and 0.5% concentrations. These findings are important to
future studies related to this form of bladder inflamma-
tion.
It is notable that in the present studies there was an appar-
ent temporal dissociation between local tissue inflamma-BMC Urology 2006, 6:2 http://www.biomedcentral.com/1471-2490/6/2
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tory changes and the enhancement of reflex responses to
bladder stimulation: statistically significant evidence of
inflammation occurred prior to (4 and 12 hr) the develop-
ment of robust and statistically significant enhancement
of ABP and EMG responses to UBD which only occurred
24 hr after administration of zymosan. This peak time-
point for reflex enhancement was the peak time of inflam-
mation as measured by Evan's Blue extravasation and so
there was, at the very least, a rough correlation between
the two endpoints. This observation is similar to those
noted in studies using the stimulus of colorectal disten-
sion in which turpentine was used as an inflammatory
agent [10]. In that study, there were early indications of
inflammation but a robust enhancement of nociceptive
responses required a longer period of time (24 hr) to
become manifest. It is possible that the underlying physi-
ological changes produced by zymosan-induced inflam-
mation requires time for expression; perhaps due to
delays related to axonal transport from the periphery to
the central nervous system of an inflammogen-induced
signal. Alternatively, it may be the case that the nocicep-
tive measures are less sensitive than the employed meas-
ures of inflammation.
The neurophysiological basis for the presently observed
increase in sensitivity of the bladder due to zymosan pre-
treatment is, as yet, unknown although both central and
peripheral mechanisms of sensitization associated with
bladder inflammation have been proposed [20]. Leading
theories include the recruitment of previously "silent"
nociceptors by pathological processes such as inflamma-
tion [21] or the sensitization of spinal dorsal horn neu-
rons by the release of neuropeptides or glutamate [22].
These processes are not mutually exclusive and each may
have variable relevance to acute versus chronic visceral
pain disorders. A combination of both peripheral and
central phenomena is likely in most acute pathological
disorders whereby the activation of a specific subset of
afferent neurons may lead to alterations in central nervous
system processing. This has been demonstrated in models
of somatic inflammatory pain and extrapolations to vis-
ceral models have been proposed [20]. The present study
provides important parametric analyses related to
zymosan-induced inflammation and secondary reflex
changes that may allow investigators to use this form of
inflammatory change in correlative neurophysiological
studies.
The relation of inflammatory changes induced by topi-
cally applied agents to chronic pain disorders is also yet to
be determined. Subjects with the painful bladder disorder
interstitial cystitis typically describe their painful sensa-
tions as being similar to a urinary tract infection with its
associated inflammation-induced hypersensitivity. The
similarity of sensory reports from interstitial cystitis and
urinary tract infections implies a similarity in neurophys-
iological changes along the neural pathway associated
with bladder sensation. The precise level at which this
convergence occurs can only be defined with a precise def-
inition of the pathways involved with at least one of the
sensations. Psychophysical studies of subjects with inter-
stitial cystitis recently reported by ourselves [23] demon-
strated subjects with interstitial cystitis to be
hypersensitive to bladder distension as well as other to
other deep tissue stimuli. This suggests altered central
processing of sensory data, a phenomenon known to
occur following inflammation in somatic systems which
is generally described in terms of hyperalgesia (magnified
responses to painful stimuli) or allodynia (pain evoked by
normally non-painful stimuli). In the present study, reflex
responses to UBD were magnified by zymosan applica-
tion at intensities of 20 mm Hg or greater. Others [e.g.,
[20]] have proposed that UBD becomes "noxious" to rats
when distension pressures exceed 40 mm Hg. This would
suggest that the augmentation of responses to UBD pro-
duced by zymosan are at the very least representative of a
visceral hyperalgesia-related phenomena and may even be
related to phenomena such as allodynia. The difficulties
of interpretation inherent to cross-species comparisons of
subjective sensations limits further speculation.
Conclusion
The present study parametrically examined responses to
the intravesical administration of zymosan and demon-
strated that this substance inflamed the bladder within 4
hr of administration and produced maximal inflamma-
tion 24 hr after topical administration. Statistically signif-
icant increases in ABP and EMG responses to UBD also
occurred 24 hr post-zymosan administration but not at
earlier timepoints. This suggests that any subsequent stud-
ies utilizing a single dose of intravesical zymosan to
inflame the bladder would be optimized by a protocol in
which pretreatment with a zymosan solution occurs 24 hr
prior to subsequent measures.
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ABP – arterial blood pressure
EMG – electromyogram
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